Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04347226
Recruitment Status : Terminated (Interim analysis indicated that futility boundary was reached.)
First Posted : April 15, 2020
Last Update Posted : November 30, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
Matthew Dallos, Columbia University

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : March 1, 2021
Actual Study Completion Date : March 1, 2021